Rafa Laboratories

Company Overview

Snapshot

Founded in January 1937, Rafa Laboratories operates with 51–200 employees. The company was acquired by FIMI Opportunity Funds in October 2020, a significant milestone in its long history.

Business overview

Rafa Laboratories is a pharmaceutical company specializing in the marketing, manufacturing, and distribution of consumer health products, including proprietary and generic prescription and over-the-counter medicines. The company develops a wide variety of medications through in-house research and external agreements, serving the pharmaceutical and healthcare industries in markets such as Israel and Germany. Rafa Laboratories also markets drugs produced by international corporations, positioning itself within the Health Tech & Life Sciences sector, with a focus on Pharma & Medical Biotechnology and Drugs Discovery & Development.

Strategic signal

In November 2025, Rafa Laboratories was awarded up to $186 million by BARDA to develop a life-saving intramuscular TXA injection for prehospital care. This substantial grant underscores the company's critical role in biodefense and medical countermeasures, signaling strong governmental validation and potential for significant impact in emergency medicine.

Company Intelligence Q&A

What was a key strategic development for Rafa Laboratories in 2020?

In October 2020, Rafa Laboratories was acquired by FIMI Opportunity Funds, marking a significant change in ownership and strategic direction for the company.

What significant FDA approval did Rafa Laboratories receive in 2022?

In August 2022, Rafa Laboratories received FDA approval for its life-saving midazolam autoinjector, designed to treat seizures caused by nerve agent exposure.

What was the nature of the collaboration agreement signed in May 2019?

In May 2019, Rafa Laboratories signed a collaboration agreement with Panaxia and PlantEXT to research and manufacture the first medical cannabis suppositories for patients suffering from inflammatory bowel disease.

What major grant did Rafa Laboratories secure in November 2025?

In November 2025, Rafa Laboratories was awarded up to $186 million by BARDA to develop a life-saving intramuscular TXA injection for prehospital care, highlighting its role in chemical, biological, radiological, and nuclear hazards medical countermeasures.

What was the outcome of FIMI's offer for sale of Rafa Laboratories in July 2026?

In July 2026, FIMI's offer for sale of Rafa Laboratories resulted in NIS 500 million, indicating a significant financial transaction for the company's controlling investor.